feisty
Extended CEO leave happens more than Australian boards publicly acknowledge. Health, family crisis, regulatory investigation, mental health: the reasons vary, but the immediate problem is the same. A business with hundreds or thousands of employees, a board with fiduciary obligations, and a market that wants certainty suddenly has none of those things aligned. What happens in the first 48 hours is rarely in any policy document.
Why the first announcement matters so much
The market reads silence as concealment. A company that announces its CEO is on "a period of leave" without naming an acting leader, a timeframe, or a governance structure will lose ground fast. Analysts start asking questions the board isn't ready to answer, and institutional shareholders start calling. The announcement is not a communications exercise. It's a governance decision made public, and vague language is its own signal.
Most ASX-listed companies default to one of three moves: appointing the COO as acting CEO, elevating the CFO, or activating the deputy CEO title if one exists. Each carries different consequences. The COO appointment reads as operational continuity. The CFO appointment reads as financial risk management, and often triggers speculation that something structural is wrong. The deputy CEO, if the title exists at all on the org chart, is typically the clearest signal that the board planned for exactly this scenario.
Boards that handle the transition well have usually done one thing differently: they've had the conversation before the event. The companies that stumble tend to be the ones where succession planning existed as a document, not a practice.
The acting CEO problem
Being named acting CEO is not the same as being CEO. The distinction matters more than most people inside the business want to admit. An acting leader faces three constraints a permanent CEO doesn't: a finite mandate that discourages long-term decisions, a market that treats every move as provisional, and a leadership team that knows the situation is temporary.
Large strategic calls made during extended acting periods often get reversed or relitigated when the permanent CEO returns. That's expensive. It's also demoralising for the executive who made the call. The board's job during this period isn't just to keep the lights on. It's to define clearly what decisions require board sign-off versus what sits with the acting leader, and to put that in writing before the first Monday morning.
The CFO-as-acting-CEO scenario deserves particular attention. As explored in coverage of when the CFO is also the acting CEO, this arrangement is common and consistently misread. The CFO brings financial discipline and board credibility, but the role change creates a governance gap: who owns the numbers when the CFO is running the business?
What boards actually get wrong
Three patterns repeat across poorly managed CEO leave events on the ASX.
First, boards underestimate the duration. Leave that starts as two weeks frequently extends to two months. Companies that make an interim appointment premised on a short return find themselves trapped: the acting leader can't commit to anything meaningful, but the permanent CEO isn't back. Strategic momentum stalls.
Second, boards fail to brief the leadership team before the market. Senior executives who learn about their CEO's leave from an ASX announcement rather than from the board chair spend the next week managing their own uncertainty rather than the business. That's a week of lost leadership capacity at exactly the wrong time.
Third, boards confuse a succession plan with a leave management plan. Succession planning, done well, identifies who the next permanent CEO should be. Leave management is a different exercise: it's about continuity of authority, not continuity of leadership identity. A company can have a robust succession plan and still handle an extended leave badly.
The deputy CEO title, when it exists, is almost always created with this scenario in mind. As analysis of when the deputy CEO title appears on an ASX org chart has shown, the role is rarely created without a specific event driving it. Boards that have given that title to someone have, in effect, pre-answered the leave question. Boards that haven't face a harder conversation in a compressed timeframe.
The return problem no one plans for
The CEO's return creates its own governance risk. An acting leader who has run the business for three or four months, made real decisions, and built relationships with the board in a new configuration does not simply hand back the keys. The power dynamic has shifted, even if the org chart says otherwise.
How that handover is managed determines whether the business exits the period with its leadership team intact. A returning CEO who underestimates how much has changed, or who immediately reverses decisions the acting leader made, signals to the senior team that nothing done in the interim was real. That erodes the credibility of everyone involved.
The board chair plays a decisive role here. The best outcomes come when the chair has kept the returning CEO informed throughout the leave period, not just updated on results but genuinely involved in the shape of decisions being made. The worst outcomes come when the returning CEO walks in to a business that feels like it was run without them, because functionally, it was.
What this reveals about governance maturity
Extended CEO leave is, in the end, a stress test of governance. Companies with mature boards, clear authority frameworks, and honest succession conversations handle it without lasting damage. Companies where the board has deferred those conversations find out the cost of deferral all at once.
The ASX Corporate Governance Council recommends that boards maintain succession plans for the CEO and other senior executives, but the guidance on acting arrangements during leave is sparse. Most companies are working from internal policy that was written once, never tested, and hasn't been updated since the last board refresh.
The companies that do it well treat this scenario the same way they treat any other foreseeable risk: they name it, assign it, and rehearse it before it's urgent. The ones that don't tend to find out what they missed at the worst possible moment.